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Abstract
Genes of the S100 fused-type protein (SFTP) family are clustered within the epidermal differentiation complex and encode
essential components that maintain epithelial homeostasis and barrier functions. Recent genetic studies have shown that
mutations within the gene encoding the SFTP filaggrin cause ichthyosis vulgaris and are major predisposing factors for
atopic dermatitis. As a vital component of healthy skin, filaggrin is also a precursor of natural moisturizing factors. Here we
present the discovery of a member of this family, designated as filaggrin-2 (FLG2) that is expressed in human skin. The FLG2
gene encodes a histidine- and glutamine-rich protein of approximately 248 kDa, which shares common structural features
with other SFTP members, in particular filaggrin. We found that FLG2 transcripts are present in skin, thymus, tonsils,
stomach, testis and placenta. In cultured primary keratinocytes, FLG2 mRNA expression displayed almost the same kinetics
as that of filaggrin following Ca
2+ stimulation, suggesting an important role in molecular regulation of epidermal terminal
differentiation. We provide evidences that like filaggrin, FLG2 is initially expressed by upper granular cells, proteolytically
processed and deposited in the stratum granulosum and stratum corneum (SC) layers of normal epidermis. Thus, FLG2 and
filaggrin may have overlapping and perhaps synergistic roles in the formation of the epidermal barrier, protecting the skin
from environmental insults and the escape of moisture by offering precursors of natural moisturizing factors.
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Introduction
The skin functions as an effective barrier protecting the body
from potentially damaging environmental influences [1]. The
surface-exposed epidermis, a self-renewing stratified squamous
epithelium composed of several layers of keratinocytes, is most
important for the barrier defense against these challenges [2].
Keratinocytes in the outmost stratum corneum (SC) of the
epidermis are sloughed off and replaced by newly differentiated
cells originating from epidermal stem cells located in the basal
layer [3,4]. The cornified envelope (CE), a prominent feature of
the SC, is a rigid and insoluble protein structure, which determines
essential properties of the barrier function [5,6].
Over the last two decades much effort has been made to
uncover the molecular bases underlying the CE barrier function
[6]. In humans many genes, involved in formation of the CE or in
regulation of keratinocyte terminal differentiation, are clustered
tightly within the epidermal differentiation complex (EDC), a 1.9-
Mb locus on human chromosome 1q21 [7,8]. With the exception
of two single genes encoding involucrin and loricrin [9,10], they
are organized into four gene clusters: small proline-rich region
genes, encoding proteins that are cross-linked to the CE proteins
[11,12]; late cornified envelope genes, encoding a group of
proteins that have distinct functions [13]; S100 genes, encoding a
large family of EF-hand calcium-binding proteins involved in the
regulation of various cellular processes including cell growth and
cell cycle regulation, differentiation, transcription and motility
[14,15]; and S100 fused-type protein (SFTP) genes (see below).
A total of five genes have been identified within the SFTP gene
cluster in humans and mice, including filaggrin (FLG) [16,17],
trichohyalin (TCHH) [18], hornerin (HRNR) [19–21], repetin (RPTN)
[22,23] and cornulin (CRNN) [24,25]. SFTP genes consist of three
exons, a tiny untranslated exon 1, a small exon 2 containing the
translation start site and encoding a 46-residue S100 domain, and
a large exon 3 encoding an EF-hand domain and internal tandem
repeats, which are characteristic of CE precursor proteins. The
best characterized SFTP gene is the FLG gene encoding
profilaggrin, a precursor protein generating mature filaggrin units.
The liberated filaggrin is an essential component of the SC that
participates in the aggregation of keratin filaments into bundles
and promote the flattened shape of dead-cell remnants [6,16,26],
while the amino-terminal domain of filaggrin enters the nucleus,
where it may have a role in regulating terminal differentiation
[27]. In the other hand, filaggrin is eventually degraded into free
amino acids that carry out various functions in the upper cornified
cells including water retention by forming part of the Natural
Moisturising Factors (NMF) of the SC. Trichohyalin, another
member of the SFTP family, functions in specialized epithelial
tissues by contributing to greater mechanical strength [28,29]. In
hair follicles, trichohyalin is cross-linked to either itself or other CE
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of the inner root sheath (IRS) and the medulla of the hair shaft
[29–32], whereas filaggrin is proposed to be cross-linked by
TGase1 [6,33] and is specially localized in the granular and
cornified cells that surround hair follicles [34,35]. Recently we
have identified hornerin as components of the SC and the outer
root sheath (ORS) of normal human hair follicles [21]. These
findings suggest different SFTP members play distinct roles in skin
barrier function.
It has been discovered that common loss-of-function mutations
within the FLG gene cause ichthyosis vulgaris, one of the most
common heritable disorders of cornification, and represent major
risk factors for atopic dermatitis (AD) and secondary allergic
diseases [36–38]. These studies underline the key role for impaired
skin barrier function in the development of AD. However, the
complexity of the AD genetics cannot be completely explained
through studies on FLG pathology, suggesting additional modify-
ing genes may also contribute to the phenotypic spectrum of AD
[39]. Although the SFTP gene cluster has long been known, the
gene content of this cluster remains unclear.
A recent study reported the presence of partial mRNA encoding
filaggrin-2 (FLG2), a novel member of the SFTP gene family, in
human keratinocytes and described its gene structure and tissue
expression [40]. Here, we report complete identification and
detailed expression analysis of this new gene. We found FLG2
expression in several tissues including healthy human skin
obtained from different body sites and an upregulation of FLG2
mRNA upon Ca
2+ stimulation in cultured keratinocytes. We could
demonstrate that the filaggrin-2 protein is proteolytically processed
and deposited in the epidermis and is localized in the granular and
cornified layers of human skin.
Results
Identification of the human filaggrin-2 gene within the
SFTP genes cluster
To search for additional S100 fused-type proteins within the
SFTP genes cluster, a BLAST search with the N-terminal 82
amino-acid sequence of filaggrin was performed and identified
several putative gene loci. One of these hits was located within the
EDC region harbouring the SFTP gene cluster and between the
two known genes FLG (GenBank NM_002016) and CRNN
(GenBank NM_016190) (Fig. 1A). We then retrieved this
theoretical 82 amino-acid sequence to screen for matching
candidates in available databases for human peptide, cDNA,
and EST sequences but failed to find any hit (data not shown),
suggesting that this genomic locus represents a novel gene. In view
of its gene location, we proposed that this gene may be a new
member of the SFTP gene family. To investigate this possibility, a
theoretical partial cDNA sequence was generated by predicting
the exonic sequence around this genomic locus with the FSPLICE
program. This method allowed us to find two potential exons
encoding the related full-length amino-acid sequence of a protein.
To verify the predicted sequence and determine its full-length
cDNA sequence, a strategy combining 59/39RACE and short-
range overlapping PCR was used. The 59RACE and the nested
PCR with reverse-transcribed RNAs from human foreskin-derived
primary keratinocytes resulted in only one product. Mapping of
this 59-extended sequence determined the first exon (51 bp), the
second exon (160 bp) and a part of the third exon (Fig. 1B). The
39-extended sequence was determined by 39RACE, which includes
a polyadenylation signal site (AAUAAA) situated eleven nucleo-
tides from its 39 extremity. After further verification of the full-
length cDNA sequence (9147 bp) with short-range overlapping
PCRs, it was registered as ifapsoriasin with the gene symbol IFPS
under the GenBank accession number AY827490. Later on, an
approved gene name filaggrin-2 (gene symbol FLG2) was suggested
by the HUGO/GDB Nomenclature Committee. Comparison
between the cDNA and genomic sequences of human FLG2
revealed the presence of 3 exons and 2 introns (Fig. 1B). All the
splice donor and acceptor sites conform to the GT/AG rule.
FLG2 encodes a S100 fused-type protein
The FLG2 gene contains an open reading frame of 7176
nucleotides, encoding a protein of 2391 amino acids. By using
SMART to explore domain architectures, this deduced protein
sequence harboured an S100/ICaBP type calcium binding
domain (residues 4–46) [41] and an EF-hand domain (residues
Figure 1. Molecular identification of the FLG2 gene. (A) Schematic physical map of human SFTP genes locus (1q21.3). Genes are ordered from
centromere to telomere. TCHH, trichohyalin; RPTN, repetin; HRNR, hornerin; FLG, filaggrin; FLG2, filaggrin-2; CRNN, cornulin; LCE5A, late cornified
envelope 5A. (B) Schematic diagram of the FLG2 gene, based on a composite cDNA isolated from foreskin-derived keratinocytes identified by
overlapping RT-PCR and RACE-PCR. It consists of three exons and two introns. The positions of the exons (boxes) and introns (curve lines) of FLG2 are
deduced by comparing its full-length cDNA sequence with the corresponding genomic DNA. 59- and 39-untranslated regions and coding sequences
are indicated by empty and black-filled boxes, respectively. The full-length nucleotide sequence has been submitted to the Gen-Bank
TM Bank with the
accession number AY827490.
doi:10.1371/journal.pone.0005227.g001
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the computer program RADAR, followed by manual adjustment,
revealed that this protein contains a large central repetitive region
consisting of two types of multiple tandem repeats (Fig. 2A).
Amino acid sequence comparison of all currently known human
SFTPs, including profilaggrin, trichohyalin, repetin, cornulin,
hornerin and filaggrin-2, indicated that they are highly conserva-
tive in inferring homology of the N-terminal 81-residue region
containing the S100 and EF-hand domains (Fig. 2B).
In particular, the filaggrin-2 protein is characterized by two
arrays of ordered repetitive structures separated by a spacer
sequence (residues 1154–1222) (Fig. 2A). The A-type repetitive
domain region is located between residues 467 and 1153, the
middle part of filaggrin-2. It is comprised of nine conserved
repeats, each having a size of 75,77 amino acids (A1 to A9)
characterized with four regularly spaced phenylalanine residues
twelve amino acids apart (Fig. 2C). The B-type repetitive domain
region is located between residues 1246 and 2303 and just in front
of the C-terminal 88-residue domain. It is comprised of fourteen
conserved repeats of 75,77 amino acids (B1 to B14), but these
repeats do not have any regularly spaced phenylalanine (Fig. 2D).
By using these tandem repeats as queries in BLAST homolog
searches against the human protein database, the most positive hit
homologous to each A-type repeat was from repetitive domains of
hornerin (50–77% identity) whereas that homologous to each B-
type repeat was from filaggrin units (28–39% identity) (data not
shown). Multiple alignments of these repeat domains together with
one representative peptide of their corresponding homolog,
respectively, further addressed their homology relationships
(Fig. 2C and D). In addition, a neighbour-joining tree was
constructed based on alignment of all FLG2 repeats together with
their representative homologous repeat units of filaggrin and
hornerin, demonstrating different evolutionary histories for the A-
type and B-type repeats (Fig. 3).
Analysis of the overall amino acid composition of both the A-
type and B-type domain revealed that they are particularly rich in
two hydroxyl amino acids serine and threonine: from 32.61% in
A-type repeats to 32.23% in B-type repeats. In addition, the A-
type and B-type repeats have high glycine contents of 28.82% and
17.39%, respectively; the A-type repeats have high glutamine
contents of 14.99%, whereas the B-type repeats have less
glutamine (8.41%) but instead more basic amino acids histidine
(14.93%) and arginine (8.32%). Most repeats except A1, A7, A9,
B1 or B4 lack any lysine donor residue, yet rich with glutamine
acceptor residues, raising the possibility that these repeat units may
act as a glutamine acceptor site for the formation of transgluta-
minase-catalyzed N
e(c-glutamyl)-lysyl isopeptide bonds [42].
Expression of FLG2 mRNA
To determine the expression profile of FLG2, we first compared
its expression with that of the FLG gene by using reverse
transcriptase PCR (RT-PCR) analyses. As shown in Fig. 4A, both
transcripts were detected in skin, thymus, stomach, tonsils, testis
and placenta, but not in heart, brain, liver, lung, bone marrow,
small intestine, spleen, prostate, colon, or adrenal gland (data not
shown). Whereas FLG transcripts were detected in kidney,
pancreas, mammary gland, bladder, thyroid, salivary gland and
trachea, FLG2 transcripts were not (Fig. 4A). To further analyze
FLG2 gene expression in human healthy skin, various tissue
specimens from different body sites were investigated by
quantitative real-time PCR. FLG2 was expressed in all normal
skin samples tested (Fig. 4B). In addition, FLG2 mRNA level did
not show significant differences among different localizations
investigated and its absolute copy number was about 6–30 copies
per 10 ng of total RNA.
To better understand its ubiquitous expression in the skin, FLG2
mRNA expression was further investigated in cultured keratino-
cytes derived from human foreskin. In response to Ca
2+
stimulation, a well-known stimulus to trigger keratinocyte
differentiation in vitro [43,44], the relative expression level of
FLG2 transcripts was elevated ,200-fold after four days and
continuously increased during further keratinocyte differentiation
(Fig. 4C). As a control to monitor the keratinocyte differentiation,
the FLG transcript level was also observed and increased similar to
that of FLG2 transcripts (Fig. 4D). This observation coincided with
the observation that FLG2 is only expressed in the uppermost
epidermal layers of healthy skin (see below), supporting the idea
that terminally differentiating keratinocytes represent the major
cellular source of FLG2 in the skin.
The filaggrin-2 protein is localized to the granular and
horny layers of the epidermis
To evaluate the expression of the FLG2 protein, goat polyclonal
antibodies against rFLG2-S were generated and used for analysis
of FLG2 expression in healthy human tissues and cells. The FLG2-
S peptide was used for immunization because it is located within
the spacer region of FLG2 exhibiting the least sequence similarity
to the other SFTP members. In immunohistochemical studies, the
FLG2 immunoreactivity was detected weakly in the esophagus,
tonsils and testis (Fig. S1), but strongly in the stratum granulosum
(SG) and stratum corneum (SC) layers of human skin (Fig. 5A). All
skin samples investigated exhibited the same staining pattern.
Exemplarily, localizations of immunoreactive FLG2 in palmar
(Fig. 5A-a) and plantar skin (Fig. 5A-c) as well as in the facial
region (Fig. 5A-b) are shown. In scalp hair follicles, the FLG2
immunoreactivity was found to be mainly restricted within the
granular and cornified cells surrounding the infundibular outer
root sheath (ORS) though weak immunoreactivity was also present
in central and proximal ORS (Fig. S1).
Sub-cellular localisation of FLG2 was further analyzed by
immunoelectron microscopy. By using the LR-White resin-
embedded samples of prefixed skin biopsy specimen from the
knee, FLG2 labelling was observed in both, the granular and
cornified cell layers (Fig. 5B-a and -b). FLG2 labels were dispersed
diffusely throughout the cytoplasm in the SC, while in the SG,
FLG2 was localized to irregularly-shaped keratohyalin granules of
various sizes (Fig. 5B-c and -d). These data suggested that the
localization of FLG2 is similar to that of filaggrin, as previously
reported [45]. Therefore, the spatial localisation of FLG2 in
comparison with that of filaggrin was further analysed by
immunofluorescent staining and laser scanning confocal micros-
copy. As shown in Fig. 6, both FLG2 and FLG were mainly
expressed in the granular layers of human skin. Although the
merged image showed that they exhibit similar spatial distribution,
only partial co-localization was observed.
To get a more deep insight into its biological function, we
performed Western blot analyses to examine FLG2 expression and
protein processing in the skin (Fig. 7A). Using detergent-free
conditions, we observed very faint staining in both the epidermal
extract (,65 kDa) and the SC extract (,65 kDa and ,15 kDa)
(lane 1 and 5). When extraction was performed in the presence of
SDS, the epidermal extract exhibited two strong bands, one
corresponding to the expected molecular mass of full-length FLG2
(,248 kDa) and another corresponding to a fragment at ,65 kDa
(lane 2). Subsequent treatment of the extract with DTT-containing
buffer resulted in extraction of additional FLG2 bands corre-
sponding to 40, 30, 25, and 20 kDa size, respectively (lane 3). In
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PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5227Figure 2. Structural characteristics of the filaggrin-2 protein. (A) A schematic diagram of human filaggrin-2. The N-terminal S100 and EF-hand
domains were detected with the SMART algorithm. Repeat domains (A1 to 9 and B1 to14) were first detected by the RADAR program and then
refined manually. (B) Multiple sequence alignment of N-terminal S100 domains from all known SFTP proteins. The alignment was generated by using
M-COFFEE and displayed by using GeneDoc. Identical residues are boxed in black while gray boxes mark partially conserved residues. The darker the
shading, the more the amino acids are conserved among SFTP members. The positions of the S100 and EF-hand regions are indicated above the
alignment. FLG, filaggrin; FLG2, filaggrin-2; HRNR, hornerin; RPTN, repetin; TCHH, trichohyalin; CRNN, cornulin. (C–D) Multiple sequence alignment of
A-type (C) and B-type repeats (D) of FLG2, respectively. The alignment was generated by using M-COFFEE and displayed by using GeneDoc. Identical
residues are boxed in black while gray boxes mark partially conserved residues. The darker the shading, the more the amino acids are conserved
among repeat domains. Here, HRNR represents hornerin (GeneBank Accession No. GI:57864582) residues 1807–1884; FLG represents profilaggrin
(GeneBank Accession No. GI:60097902) residues 3745–3821.
doi:10.1371/journal.pone.0005227.g002
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stronger small-size FLG2 bands, especially a 15-kDa size band,
but without a clear band at the size of full length FLG2 (lane 6 and
7). Interestingly, extracts obtained from further treatment of the
SC sediment with trypsin did not abolish any FLG2-immuno-
staining but resulted in broad intense bands between 45 and
72 kDa (lane 8).
Filaggrin-2 expression in psoriasis vulgaris and atopic
dermatitis
To characterize FLG2 expression in inflammatory cutaneous
diseases, lesional and non-lesional skin of patients suffering from
psoriasis and atopic dermatitis were investigated. Psoriatic lesions
(n=3) exhibited decreased FLG2 immunoreactivity, whereas the
non-lesional skin of the same patients exhibited a similar staining
pattern as that of healthy individuals (Fig. 8A-a and -b). In contrast,
there were no obvious staining differences observed between the
lesional skin of AD patients and the non-lesional skin of the same
patients and healthy individuals (n=3; Fig. 8B-a and -b).
Discussion
In the current study we have identified and characterized the
FLG2 gene (GenBank accession number AY827490) as a
member of the SFTP gene family. A recent paper described
this gene based on the registered AY827490 gene and publicly
available DNA data [40]. While supporting keratinocyte
expression of FLG2 as the major cellular source [40], our data
are inconsistent with their conclusion that FLG2 expression is
restricted to the epidermis. Our data show that in addition to
skin, FLG2 mRNA is also present in thymus, stomach, tonsils,
testis and placenta (Fig. 4). This discrepancy may be the result of
the inherent technique difficulties of RT-PCR analysis, which we
have previously addressed [21]. Indeed, in consideration of high
sequence similarities between each other among the 59-end
regions of all the SFTP gene members, it seems that the design of
specific primers emerges as a key barrier to successfully
distinguish various SFTP members. In our study, we have
developed two specific primer pairs that can uniquely amplify
the FLG2 gene with the Primer Unique program.
In contrast to the proposed classification of the FLG2 repeats
[33], we suggest that FLG2 can generate two kinds of repeat units
with homology to filaggrin and hornerin, respectively (Fig. 2).
There are nine A-type internal repeats, which display high identity
to hornerin, and fourteen B-type internal repeats, which resemble
those of filaggrin. The phylogenetic tree constructed based on their
amino acid sequences supports the above idea (Fig. 3). Further-
more, both repeat domains of FLG2 contain a high proportion of
histidine and glutamine residues, the source of the natural
moisturizing factors urocanic acid and pyrrolidone carboxylic
acid, suggesting FLG2 may contribute to maintaining SC
hydration as proposed for filaggrin [46].
Similar to that of the FLG gene [16,47], the final huge exon of
the FLG2 gene contains highly GC-rich repeats with similar
nucleotide sequences. Such properties may cause technical
problems for PCR-based amplification and subsequent sequenc-
ing, as was also reported for analyzing the plectin gene [48] and
the FLG gene [49]. The reason is that GC-rich templates
frequently generate local secondary structures leading to an
inefficient PCR amplification [50]. Therefore, it is a technical
challenge to efficiently clone and sequence the full-length cDNA
of this kind of genes. In this study, a comprehensive strategy has
been developed by combining bioinformatic analysis, RACE and
short-range overlapping PCR to overcome PCR problems and
subsequent sequencing steps to yield the full-length cDNA
sequence of the FLG2 gene. This strategy seems to be the best
way to analyze a gene like FLG2 with highly similar sequences
and GC-rich repeats at DNA level. More importantly, the
primer pairs used for successful determination of FLG2 cDNA
(Table 1) should be crucial for detailed functional analyses of the
FLG2 gene in the future. Indeed, we have failed to clone the
length cDNA sequence of FLG2 by long-distance RT-PCR (data
not shown).
In the epidermis and hair follicles, the localization of FLG2 is
similar to that of filaggrin but is different from that of hornerin
or trichohyalin [21,45]. FLG2 immunoreactivity is present as
FLG2 granules in granular cells but is diffusely distributed in the
cytoplasm of cornified cells (Fig. 5). However, FLG2 and
Figure 3. Unrooted tree of filaggrin-2 repeat domains together
with typical domains of hornerin and profilaggrin. This
neighbour-joining cladogram tree [68], depicting relationships among
A- and B-type repeats, is constructed based on the alignment. The
bootstrap consensus tree is inferred from 1000 replicates [69]. Branches
corresponding to partitions reproduced in less than 50% bootstrap
replicates are collapsed. The tree is drawn to scale, with branch lengths
in the same units as those of the evolutionary distances used to infer
the phylogenetic tree. All positions containing gaps and missing data
were eliminated from the dataset (complete deletion option). There
were a total of 71 positions in the final dataset. Phylogenetic analyses
were conducted in MEGA4 [66]. Numbers in nodes correspond to
bootstrap support values indicated as percentages.
doi:10.1371/journal.pone.0005227.g003
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data suggest that FLG2 and filaggrin might have not any direct
intermolecular cross-linking between each other but may play a
similar role in skin biology. Profilaggrin is an insoluble, highly
phosphorylated protein, which consists of multiple FLG units
joined by linker peptides [51,52]. During terminal differentiation
this protein is dephosphorylated and processed by several
endoproteases to generate two major products: FLG and the
N-terminal peptide [27]. FLG mainly functions to aggregate
keratin filaments leading to keratinocyte compaction and
formation of the SC [6] by conjugation of glutamine-rich
linkage proteins with lysine-rich proteins like P-cystatin, a known
cross-linking partner of filaggrin in the SC [53]. A similar
mechanism can be suggested for FLG2 repeats to aggregate
lysine-rich proteins because these repeats almost lack cysteine or
lysine residues but contain high glutamine contents, implicating
that they may act as amino acceptors in transglutaminase-
catalyzed reactions to generate glutaminyl-lysine cross-links with
neighbouring proteins [54]. The cross-linking possibility of
FLG2 is supported by the detection of natural FLG2 proteins
under reducing conditions (Fig. 7). The absence of a clear full-
length FLG2 band in the SC extract suggests that FLG2 is
processed within the stratum granulosum. However, because of
the existence of different FLG2 intermediates in the SC, further
protein processing can be expected to happen in order to
completely generate mature FLG2 repeat domains. This
observation is consistent with data from profilaggrin, where an
N-terminal peptide of 32 kDa is released after proteolytic
processing [55], suggesting the processing of the N-terminal
domain of FLG2 could be similar to that of filaggrin.
Common loss-of-function mutations within the FLG gene
causing ichthyosis vulgaris, filaggrin units represent major risk
factors for atopic dermatitis (AD) and secondary allergic diseases
[36–38]. In the investigation of FLG2 immunoreactivity in skin
biopsies from patients with AD and psoriasis vulgaris, two of the
most common inflammatory skin diseases, we have observed
decreased expression of FLG2 only in the lesional but not in
uninvolved skin of psoriasis patients. Because FLG2 expression
strongly depends on terminal differentiation of keratinocytes, the
decreased expression of FLG2 might be caused by the altered
differentiation in the psoriatic plaques. Indeed, reduced expression
of FLG has also been reported for psoriasis lesions [56], though
FLG null alleles are not associated with psoriasis [57]. In contrast,
it has been reported that hornerin, another member of the SFTP
family, is strongly expressed in psoriatic lesions [20]. In AD
patients, no obvious differences have been observed for FLG2
expression in lesional and nonlesional skin. Since the number of
patients investigated was limited (n=3), it might be still of interest
to investigate the association of the FLG2 expression and AD in
larger cohorts.
Figure 4. Expression analyses of FLG2 transcripts. (A) Expression profile of FLG2 and FLG mRNA. Fragments were obtained after RT-PCR
amplification on multiple human tissue cDNAs with primers specific to human FLG2, FLG and GAPDH. Lanes are labelled according to the template
tissue. M, DNA molecular weight marker. (B) FLG2 mRNA is expressed at various localizations of human skin. The mRNA expression level of FLG2 was
measured by quantitative real-time PCR in human skin samples. Data were obtained from three independent experiments with different samples of
skin and are indicated as absolute mRNA copy number per 10 ng of total RNA and as the mean+/2SD. Feet, the sole of the foot. (C–D) Comparative
analyses of FLG2 (C) and FLG (D) expression in cultured primary keratinocytes. Quantitative real-time PCR was conducted on total RNA samples
collected from keratinocytes treated with 1.0 mM CaCl2 for the indicated times. Bar graphs represent the relative mRNA expression of either FLG2 or
FLG against GAPDH. Data are obtained from three independent trials with different sources of keratinocytes and are indicated as the mean+/2SD.
doi:10.1371/journal.pone.0005227.g004
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member of the SFTP family present in the granular and horny
layers of human epidermis, which might play a role in skin barrier
networks. Future work will be necessary to determine the
processing of FLG2 repeat domain units and their biological
function.
Materials and Methods
All experiments were performed according to the Declaration of
Helsinki protocols and under protocols approved by the Ethics
Committee at the Medical Faculty of the Christians Albrechts
University, Kiel, Germany (A104/06). Normal skin specimens
were taken from routine clinical work at the Department of
Dermatology, UKSH Kiel, and represent tumour-free margins of
benign melanocytic tumours surgically removed from patients. All
specimens were obtained from patients who had signed informed
consent forms. In addition, skin samples were obtained from
untreated patients with AD and psoriasis vulgaris in local
anaesthesia. Other tissues were derived from normal individuals
posthumously during autopsy after cardiac arrest. All primers used
for various applications as described in the text were designed with
the Primer3 server [58] and ordered from Sigma–Aldrich
(Taufkirchen, Germany) (Table 1). Restriction endonucleases
were from New England Biolabs (Frankfurt, Germany). Dulbec-
co’s PBS was obtained from PAA Laboratories GmbH (Co ¨lbe,
Germany). Acetonitril, methanol and H2O (for HPLC) were
obtained from Promochem (Wesel, Germany). All other chemicals
were ordered from Sigma–Aldrich (Taufkirchen, Germany), if not
otherwise indicated.
Culture and stimulation of keratinocytes
Foreskin-derived primary keratinocytes were prepared from
neonatal foreskin after surgery following established methods [59]
and were cultured in Epilife medium in 75-cm
2 flasks (BD
Biosciences, Heidelberg, Germany) in a humidified atmosphere
with 5% CO2. For stimulation and RNA isolation, cells were
grown in 12-well tissue culture plates (4 cm
2/well; BD Biosciences)
and were used after the second passage at a confluence of 70–80%.
Stimulation was performed for the indicated time with 1.0 mM
freshly prepared CaCl2.
mRNA expression analyses
Total RNA was isolated from human skin samples or cultured
foreskin-derived keratinocytes using the RNeasy Mini kit (Qiagen,
Hilden, Germany). All other RNAs were obtained from BD
Bioscience Clontech (Heidelberg, Germany). A total of 2 mgo f
total RNA was reverse transcribed with an oligo(dT)18 primer and
Superscript II RNaseH
2 reverse transcriptase (Invitrogen, Ham-
burg, Germany). The reaction mixture was diluted 10-fold with
H2O for further PCR experiments. To design primer pairs to
uniquely amplify the FLG2 gene, all the 59-end 500-bp nucleotide
sequences of the SFTP gene family were retrieved from GenBank
and then used for primer designing by the Primo Unique program
(http://www.changbioscience.com/primo/primou.html).
Qualitative RT-PCR assay was performed with Advantage 2
Polymerase Mix (BD Bioscience Clontech, Heidelberg, Germany).
One pair of gene-specific primers FLG2-rtF and FLG2-rtR
(Table 1) were designed to overlap intron 2 of the FLG2 gene
and amplify the 198-bp cDNA target. The thermal cycling
conditions were as follows: firstly with 5 cycles at 95uC for 20 s,
68uC for 30 s; secondly 5 cycles at 95uC for 20 s, 66uC for 30 s;
then 30 cycles at 95uC for 20 s, 63uC for 30 s, 68uC for 30 s. The
PCR products were separated on a 2.0% agarose gel and then
visualized by ethidium bromide staining. The specificity of the
PCR products was confirmed by sequencing. As an internal
control of cDNA templates, the housekeeping gene glyceraldehyde
phosphodehydrogenase (GAPDH) was assessed with each cDNA in a
separate PCR reaction by one pair of intron-spanning primers
(forward primer: 59-CCA GCC GAG CCA CAT CGC TC-39,
reverse primer: 59- ATG AGC CCC AGC CTT CTC CAT-39).
Quantitative real-time RT-PCR assay was carried out with the
same primer pair as above using the SYBRH Premix Ex Taq
TM
Kit (Takara Bio, Heidelberg, Germany) in a fluorescence
thermocycler following the instructions of the manufacturer
(LightCycler, Roche Molecular Biochemicals, Hamburg, Ger-
many). Cycling conditions were: 45 cycles at 95uC for 10 s, then
Figure 5. Localization of filaggrin-2 in human epidermis. (A)
Immunohistochemical analyses of FLG2 in human skin sections. Healthy
skin sections from palmar (panel a; scale bar, 60 mm) and plantar (panel
c; scale bar, 120 mm) sites as well as the upper leg region (panel b; scale
bar, 60 mm) were stained with anti-FLG2 antibody. Specificity of
antibody was confirmed by blocking the antibody with the antigen
(panel d; scale bar, 60 mm). Representative experiments out of three are
shown. (B) Post-embedding immunoelectron microscopy of FLG2
(10 nm gold) in healthy foreskin. FLG2 labels are present in both
granular and cornified cells (panels a and b). Note that FLG2 labels are
either diffusely dispersed in the cytoplasm (panel c) or grouped as
keratohyalin granules (panel d). SG, stratum granulosum; SC, stratum
corneum.
doi:10.1371/journal.pone.0005227.g005
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measurements were taken at 72uC at the end of each cycle.
Amplicons were analysed by 2.0% agarose gel electrophoresis and,
where necessary, purified and sequenced to confirm their identity.
As an internal control to account for keratinocyte differentiation in
response to Ca
2+-stimulation, the FLG gene was measured with
each cDNA in a separate PCR reaction using intron-spanning
primers (forward primer: 59- GGC TCC TTC AGG CTA CAT
TCT A -39, reverse primer: 59- ATC TGG ATT CTT CAG GAT
TTG C -39). Cycling conditions were as follows: with 45 cycles at
95uC for 10 s, 69uC for 20 s (‘touchdown’ of 21uC/cycle to
63uC), 72uC for 15 s, then 76uC acquisition of signals. For
calculation of the relative transcripts amplification, the house-
keeping gene GAPDH was performed with each cDNA in a
separate PCR reaction by the same pair of primers as above. For
standard curve acquisition, eight serial 10-fold dilutions of
linearized plasmid DNA containing the insert were prepared for
each primer set, representing 30 to 3.0610
8 double-stranded DNA
molecules quantified by use of a BioPhotometer (Eppendorf,
Hamburg, Germany). For relative real-time PCR, the data from
one triplicate-sample result of three independent experiments were
analyzed with software (GraphPad Prism 4) and expressed as
mean6SD of mRNA in question relative to that of GAPDH. For
absolute DNA quantification, reactions were carried out with
different concentrations of linearized plasmid DNA containing the
insert in parallel to the samples that should be quantified. The data
from three independent observations were analyzed with the
software and expressed as mean6SD of mRNA copies in question
relative to 10 ng of total RNA.
In silico analyses
Homology search was done using the BLAT algorithm [60] as
provided by the UCSC Genome Browser (http://genome.ucsc.
edu/cgi-bin/hgBlat) and the BLAST algorithm [61] as provided
by the Ensembl server (http://www.ensembl.org/ Multi/
blastview). Subsequent sequence manipulations utilized the online
BLAST 2 Sequences [62] (http://www.ncbi.nlm.nih.gov/ blast/
bl2seq/bl2.html). Splice site analysis was performed using the
FSPLICE program implemented at the SoftBerry server (http://
www.softberry.com/berry.phtml). Protein domains were analyzed
on the SMART server [63]. Internal sequence repeats were
detected using the RADAR algorithm [64] and modified by
manual adjustment afterwards. Multiple sequence alignments were
performed using the M-coffee program [65] and Neighbor-Joining
trees were constructed in MEGA4 [66]. Alignments were edited
with GeneDoc (http://www.psc.edu/biomed/genedoc).
Determination of the full-length sequence of FLG2 cDNA
Total RNA was obtained from cultured human foreskin-derived
keratinocytes using TRIzol reagent (Invitrogen, Hamburg,
Germany). After treatment with RNase-free DNase I (Roche
Diagnostics, Mannheim, Germany) to exclude contamination with
genomic DNA, 3 mg of DNA-free total RNA was then used for the
first-strand cDNA synthesis for RACE (Rapid Amplification of
cDNA Ends) with SMART RACE cDNA Amplification Kit (BD
Bioscience Clontech, Heidelberg, Germany) according to the
Figure 6. Immunofluorescence localization of FLG2 and FLG in
human skin. Skin sections were stained with a mixture of anti-FLG2
and anti-FLG antibody. The images show FLG2-Alexa-Fluor as red while
FLG-FITC as green. Nuclear staining was done using DAPI. Comparative
localization of FLG2-Alexa-Fluor and FLG-FITC is shown in the merged
image. Scale bars, 30 mm.
doi:10.1371/journal.pone.0005227.g006
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FLG2-R1 and FLG2-R2 (Table 1) were designed based on the
nucleotide sequence of the putative exon 3 of the FLG2 gene and
used as antisense primers. For 39-RACE, seven specific primers
FLG2-F1,7 (Table 1) were designed against the nucleotide
sequence of the putative exons 2 and 3 of the FLG2 gene and used
as sense primers, among which each FLG2-F2,7 was used for the
second round PCR whereas FLG2-F1 was used for the first round
PCR. RACE reactions were set up as follows: 5 ml of adapted
cDNA, 0.2 mM1 0 6UPM primer, 0.2 mM gene-specific primer,
5 mlo f1 0 6reaction buffer, 0.2 mM dNTP, 1 ml of BD Advantage
2 Polymerase mix, in a final volume of 50 ml. RACE PCR was
performed on MJ Research Peltier Thermal cycler PTC-200 and
reaction cycles were as follows: 95uC for 1 min; 5 cycles of 95uC
for 20 sec, 72uC for 5 min; 5 cycles of 95uC for 20 sec, 70uC for
5 min; 25 cycles of 95uC for 20 sec, 68uC for 5 min; and a final
extension of 10 min at 68uC. Then, 0.5 ml of PCR products was
used as template for nested PCRs under the following conditions:
1 min at 95uC, 30 cycles of 20 sec at 95uC and 3 min at 70uC, and
a final extension of 10 min at 70uC.
To characterize the full-length cDNA sequence of FLG2,a n
alternative approach was used, namely the short-range overlap-
ping PCR strategy. Firstly, based on the newly defined 59- and 39-
terminal sequence, the putative middle part of mRNA sequence
was initially predicted by in silico analysis and then used for primer
design; secondly, all subsequent PCRs used primer pairs (Table 1)
designed to amplify about 0.5,1.4 kb length of overlapping
cDNA. Thirdly, to design a pair of primers, one primer maps the
previously confirmed cDNA sequence while another primer maps
the predicted DNA sequence to be tested. The first round
39RACE-PCR product was used as the template for PCR using
BD Advantage 2 Polymerase mix under the following conditions:
1 min at 95uC, 30 cycles of 20 sec at 95uC and 90 sec at 70uC,
and a final extension of 10 min at 70uC. The amplified products
were subcloned and sequenced.
Construction of prokaryotic expression vectors for FLG2
expression in E. coli
Recombinant protein expression of FLG2 cDNA in Escherichia.
coli (E. coli) was performed by molecular subcloning of a partial
FLG2 cDNA into prokaryotic expression vectors. This partial
Figure 7. Western blot analysis of filaggrin-2 in human skin. (A) Total proteins were individually extracted from SC and abdominal epidermis,
separated on an SDS-10% PAGE and blotted on a nitrocellulose membrane. The FLG2 protein was detected by using purified goat anti-FLG2
polyclonal antibody and HRP-conjugated mouse anti-goat IgG as the second antibody. Proteins were extracted sequentially from abdominal
epidermis with PBS buffer (lane 1), SDS buffer (62.5 mM Tris, 10% glycerol, 5% SDS) (lane 2), and SDS/DTT buffer (SDS buffer plus 10 mM DTT) (lane 3),
and from trypsin-digested skin sample (lane 4); alternatively, proteins were sequentially extracted from SC with PBS buffer (lane 5), SDS buffer (lane 6)
and SDS/DTT buffer (lane 7), and from trypsin-digested SC sample (lane 8). In all other lanes, 5 ml of protein extracts were loaded. The approximate
size of the protein was determined using high-molecular-weight standards. The experiment was performed twice and a representative example is
shown. (B) As a control, Western blot analysis of the purified recombinant FLG2 with a theoretical monomolecular mass of 15.66 kDa was performed
under the same assay conditions. Different amounts of protein were loaded as indicated. The ladder-like bands appeared with higher amounts of
protein.
doi:10.1371/journal.pone.0005227.g007
Figure 8. Immunohistochemical analyses of filaggrin-2 expres-
sion in skin lesions of psoriasis and atopic dermatitis. Skin
biopsies from affected and non-affected sites (upper back) on patients
with psoriasis or atopic dermatitis (AD) were stained with anti-FLG2
antibody. A) panel a, lesional psoriatic skin; panel b, non-lesional
psoriatic skin; B) panel a, lesional AD skin; panel b, non-lesional AD skin.
Representative results of three different patients of each group are
shown. Scale bars, 60 mm.
doi:10.1371/journal.pone.0005227.g008
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as a PCR fragment using Pfu TurboH DNA polymerase (Stratagene,
La Jolla, USA). Two expression vectors, pET-SUMO (Invitrogen)
and pET-32a (Novagen, North Ryde, Australia), were used in this
study. One primer pair pET-IFPS-2-F and pET-IFPS-2-R
(Table 1) was used to introduce the cloning sites BglII and NotI
sites. The PCR product was first subcloned into a pGEM-T vector
(Promega, Mannheim, Germany) and then double-digested prior
to being cloned into the similarly digested pET-32a vector. To be
subcloned into the pET-SUMO vector, the insert was generated
with the primer pair SUMO-IFPS-2-F and SUMO-IFPS-2-R.
Both constructs were transformed into E. coli TOP10 (Invitrogen)
and selected on LB agar plates containing appropriate antibiotics.
Clones were sequenced to check for any mutation that might have
been misincorporated during the amplification.
Expressionandpurificationofpolyhistidine-taggedproteins
The pET-32a-derived expression construct was transformed
into E. coli BL21trxB(DE3)pLysS cells (Novagen, North Ryde,
Australia) and selected on LB agar plates containing carbenicillin
(50 mg/ml), chloramphenicol (34 mg/ml) and kanamycin (15 mg/
ml). The pET-SUMO-derived expression construct, on the other
hand, was transformed into E. coli BL21(DE3)pLysS cells (Novagen)
and selected on LB agar plates containing kanamycin (50 mg/ml)
and chloramphenicol (34 mg/ml). Transformants were grown at
37uC and 200 rpm in LB medium containing appropriate
antibiotics to an OD600 of 0.4 to 0.6. Protein expression was
induced with 1 mM IPTG (isopropyl-beta-D-thio-galactopyrano-
side) for 3 h. After incubation, cells were harvested by centrifu-
gation and resuspended in 16LEW buffer (50 mM NaH2PO4,
300 mM NaCl, pH 8.0). Resuspended cells were subjected to
three cycles of freeze-thawing and sonicated on ice. After
centrifugation at 13,5006g for 45 min, the clarified supernatant
was applied to ProtinoHNi prepared columns (Macherey-Nagel,
Dueren, Germany) and the polyhistidine-tagged protein was
eluted with 16elution buffer (50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole, pH 8.0). The fusion protein was further
purified by reversed phase high-performance liquid chromatogra-
phy (RP-HPLC) using preparative wide-pore C8 RP-HPLC with a
column (SP250/10 Nucleosil 300-7 C8; Macherey-Nagel) that was
previously equilibrated with 0.1% (v/v) TFA in HPLC-grade
water containing 10% acetonitrile. Proteins were eluted with a
gradient of increasing concentrations of acetonitrile containing
0.1% (v/v) TFA (flow rate, 3 ml/min). Fractions containing
UV(215 nm)-absorbing material were collected, analyzed by ESI-
QTOF-mass spectrometry (Micromass, Manchester, U.K.) and
lyophilized.
Digestion and purification of recombinant proteins
The his-tagged SUMO fusion protein purified from HPLC-RP8
was cleaved with SUMO protease 1 according to the manufac-
turer’s protocol (LifeSensors Inc.). The digestion mixture con-
tained 2 units of SUMO protease 1 per 100 mg of the fusion
protein in a volume of 500 mlo f1 6PBS buffer and was incubated
for 3 h at 30uC prior to be adjusted to a pH value between 3.0 and
4.0. After a brief centrifugation, the supernatant was injected onto
a Jupiter-5m-C4-300A HPLC column (Phenomenex, Aschaffen-
burg, Germany) equilibrated with 0.1% TFA and 10% acetonitrile
in water. Peptides were eluted with a gradient of increasing
concentrations of acetonitrile containing 0.1% (v/v) TFA (flow
rate, 0.5 ml/min). Fractions of each peak were collected, analyzed
by ESI-QTOF-mass spectrometry and lyophilized.
Production of Antibodies
Polyclonal antiserum was generated in goat against the amino
acid sequence of human FLG2 (residues 96 to 235). From a total of
1.8 mg of protein mixture including 800 mg of the pET-32a-
derived fusion protein and 1 mg of the purified recombinant
protein, 1.2 mg was conjugated by the glutaraldehyde method
[67] to 1.0 mg of maleimide-activated keyhole limpet hemocyanin
(KLH) and subsequently mixed with 600 mg of the uncoupled
protein mixture for use as immunogens. Immunization of a goat
was carried out four times on days 0, 14, 28 and 35. Goats were
bled 2 weeks after the last booster. The antiserum was affinity-
purified by absorption against the HPLC-RP4 purified recombi-
nant FLG2-S (rFLG2-S) that was covalently bound to HiTrap
NHS-activated HP 1 ml columns (Amersham Biosciences, Frei-
burg, Germany). Specificity was tested by immuno-dot analyses
using rFLG2-S.
Protein extraction and Western blot analyses
Proteins were extracted from abdominal skin and pooled heel
stratum corneum (SC). The subcutaneous fat tissue was separated
Table 1. Primers used for various applications as described in
the text.
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smaller pieces. The skin or pooled SC was ground in liquid
nitrogen in the presence of washed hydrochloric acid-treated sea
sand. The fine-grained powder was added with 500 ml of PBS
containing Complete Protease Inhibitor Cocktail (CPIC; Roche
Diagnostics, Mannheim, Germany) (buffer 1) per 100 mg of skin
(or SC), vortexed thoroughly and centrifuged. Unless otherwise
indicated, all centrifugation steps were carried out at 11,9006g for
10 min. After separation of the supernatant (extract 1), the sample
sediment was resuspended in 500 ml of buffer 2 (5% SDS, 10%
glycerol, 62.5 mM Tris-HCl containing CPIC) and centrifuged.
The supernatant was collected (extract 2) and the pellet was
resuspended in 500 ml of buffer 3 (buffer 2 plus 10 mM DTT and
CPIC) and incubated for 1.5 h at room temperature before
centrifugation. This supernatant was also collected (extract 3).
Then, the sediment was washed with 100 mM NH4HCO3 to
remove residual SDS and DTT and resuspended in 150 mlo f
100 mM NH4HCO3 per 100 mg of original sample. This mixture
sample was incubated for 5 h at 37 uC with 4 mg of activated
sequencing-grade trypsin (Roche Diagnostics, Mannheim, Ger-
many). The supernatant was pooled by centrifugation.
For Western blotting, 5 ml of total proteins were separated on an
SDS-10% polyacrylamide gel (PAGE) and blotted onto a ProtranH
nitrocellulose transfer membrane (pore size 0.2 mm, Schleicher &
Schuell BioScience, Dassel, Germany). After blocking for 1 h in
5% (w/v) nonfat powdered milk and 0.05% Tween in PBS (PBS-
T), membranes were incubated at 4uC for 18 h in PBS-T
containing 3% (w/v) nonfat powdered milk and the affinity-
purified polyclonal anti-FLG2 antibody (1 mg/ml, 1:4000 dilu-
tion). Membranes were washed six times for 5 min each with PBS-
T and incubated for 1 h in PBS-T buffer containing 3% (w/v)
nonfat powdered milk and mouse anti-goat IgG HRP conjugate
(diluted 1:20,000; Dianova, Hamburg, Germany). After six times
washing prior to incubation for 5 min with chemiluminescent
peroxidase substrate, the blot was visualized with a Diana III
cooled CCD-camera imaging system (Raytest, Straubenhardt,
Germany). All experiments were performed at least twice and a
representative example was shown.
Immunohistochemistry
Frozen 5 mm tissue sections were fixed in acetone and in 4% (v/
v) paraformaldehyde before the immunoassaying. Paraffin-em-
bedded sections were deparaffinized, rehydrated and subsequently
blocked with 10% normal goat sera containing 0.1% BSA and
0.2% glycine. After brief washing in tris-buffered saline (TBS), the
sections were stained with affinity-purified polyclonal goat anti-
FLG2 antibody (1 mg/ml, 1:200 dilutions) in a humid atmo-
sphere. The sections were subsequently incubated with biotiny-
lated anti-goat IgG (Vector, Burlingame, CA), followed by
detection using the Vectastain ABC-APH system (Vector).
Haematoxylin was used for counterstaining (DAKO, Glostrup,
Denmark). Specificity test of the anti-FLG2 antibody was
performed by using rFLG2-S peptides to block the primary
antibody. Negative controls were established by using preimmune
goat sera to stain sections.
Immunofluorescence and confocal microscopy
To show the potential spatial relationships between FLG-2 and
FLG, the paraffin-embedded skin sections (5 mm) were blocked
with 10% normal goat and mouse sera (Vector) in TBS containing
0.1% BSA and 0.2% glycine after standard rehydration. For
double labeling, sections were treated as for single labeling and
incubated with a mixture of anti-FLG2 antibody (1:50 dilution)
and a mouse monoclonal anti-filaggrin antibody (1:200 dilution;
Biologo, Kronshagen, Germany) overnight at 4uC. Subsequently,
they were washed three times in PBS for 10 min and then
incubated with a mixture of secondary antibodies, AlexaFluor-
coupled chicken-anti-goat IgG (Invitrogen) and FITC-coupled
horse-anti-mouse IgG (1:400 each; Biologo, Kronshagen, Ger-
many) for 1 h at room temperature. Nuclei present in the
epidermal cells were counterstained with DAPI. To exclude
autofluorescence secondary to the preparation of the sections,
control sections were stained without primary antibodies. Slides
were analyzed using a confocal laser scanning microscopy (Zeiss,
LSM 510 UV, Jena, Germany).
Immunoelectron microscopy
Fresh skin biopsy specimen from the knee were washed twice
with PBS and fixed for 4 h on ice in 4% freshly depolymerized
paraformaldehyde and 0.1% glutaraldehyde in 200 mM sodium
cacodylate buffer (pH 7.2). The fixed tissue was washed with
buffer, dehydrated in a graded series of ethanol and embedded in
LR-White resin according to standard procedures. Polymeriza-
tionwas carried out at 4uC for 48 h under UV light. Ultrathin
sections were prepared with an UCT ultramicrotome (Leica
Microsystems, Bensheim, Germany) and placed on 50-mesh Au
Grids. Ultrathin sections were washed three times for 2 min each
with PBS containing 20 mM glycin and incubated in blocking
buffer (0,2% fish skin gelatine, 0,2% BSA in PBS) for 10 min. The
sections were incubated overnight at 4uC in anti-FLG2 antibodies,
diluted 1:100 in blocking buffer. After washing with blocking
buffer (five changes, 3 min each), the sections were incubated for
1 hour at room temperature with rabbit anti-goat coupled to 10-
nm gold (Biotrend, Ko ¨ln, Germany), diluted 1:50 in blocking
buffer. Thereafter, the sections were washed in PBS (five changes,
3 min each), fixed in 1% glutaraldehyde (3 min) and washed in
Milli-Q water (five changes, 2 min each). As a control, preimmune
serum was used. The sections were counterstained for 10 min with
2% aqueous uranyl acetate (Serva, Heidelberg, Germany).
Immunolabeled grids were analyzed using a transmission electron
microscope CM10 (Philips, Eindhoven, The Netherlands).
Supporting Information
Figure S1 Immunohistochemical analyses of FLG2 in tissue
sections and hair follicles. Anti- FLG2 antibodies were used to
stain cryosections of the kidney, esophagus, pharynx, pancreas,
tonsils, testis and hair follicles. The esophagus, tonsils and testis
show weak immunoreactivity while the kidney, pharynx and
pancreas do not. In the hair follicle, the distal parts of the outer
root sheath show the strong staining pattern, whereas in central
and proximal parts the outer root sheath epithelium show weak
immunoreactivity.
Found at: doi:10.1371/journal.pone.0005227.s001 (3.20 MB TIF)
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